As the UK prepares for the exit from the Transition Period from the EU, Novartis remains committed to driving a thriving life sciences sector in the UK and ensuring patients can continue to benefit from our medicines.
It is our priority to make sure patients throughout the UK can continue to access their medicines after the end of the transition period, on 31st December 2020. A future trade agreement between the UK and EU must prioritise the needs of patients, particularly around the supply and safety of medicines, in the UK and across Europe. We strongly believe that a future economic relationship should maintain vital areas of regulatory cooperation to minimise disruptions of the supply of medicines to patients. We continue to prepare for all scenarios and with this in mind we have maintained increased inventories across our medicines portfolio for both Novartis and Sandoz. Working together with the UK government, directly and through our trade bodies, we will seek continued cooperation between UK and EU authorities on matters essential to the supply of medicines. Therefore, we continue to work with the Department of Health and Social Care and other authorities to ensure the necessary steps are taken to achieve this. Furthermore, we are working specifically with the UK government and relevant authorities on assessing the implications of the Northern Ireland protocol with a view to minimising any potential patient disruption and ensuring continued access to medicines for patients in Northern Ireland.
At this important time for the sector, it is crucial that all parties work together in the UK/EU trade negotiations to ensure that the UK can continue to be a global leader in life sciences, delivering for patients worldwide.